

# In Vitro and In Vivo Reduction of Erythrocyte Sorbitol by Ascorbic Acid

Joe A. Vinson, Marianne E. Staretz, Pratima Bose, Hassan M. Kassm, and Barbara S. Basalyga  
Department of Chemistry  
University of Scranton  
Scranton, Pennsylvania 18510-4626

—Published in Diabetes, Vol 38, No. 8, pg 1036-1041, American Diabetes Association, August 1989.

—Presented at International Symposium on Polyol-Pathway and its Role in Diabetic Complications, Nagoya, Japan, October 1986.

—Presented at Department of Biological Sciences, University of East Anglia, Norwich, England, August 1988, titled “The Effect of Synthetic and Natural Vitamin C on Cataracts and Diabetes in Animals and Man.”

—Presented at Hospital Robert Debry, Reims, France, August 1988, under the title “Effect of Vitamin C Supplementation on Diabetes and Antioxidants on Lipid Peroxidation in Vitro and In Vivo.”

—Presented at Nuffield College of Ophthalmology, Oxford University, Oxford, England, August 1988, under the title “The Effect of Synthetic and Natural Vitamin C on Cataracts and Diabetes in Animal and Man.”

—Presented at National Institute of Health Conference on the Maillard Reaction in Aging, Diabetes and Nutrition, National Institute of Health, Beltsville, Maryland, September 1988, titled “Effect of Vitamin C on the Sorbitol Pathway and Lipid Peroxidation in Diabetes.”

**ABSTRACT — The in vitro accumulation of sorbitol by human erythrocyte incubated in a physiological glucose medium was found to be strongly reduced by the addition of ascorbic acid (AA). A maximal inhibition of sorbitol in the erythrocytes of 98.3% occurred when the concentration of AA was at its peak in the cells. After incubation, the erythrocyte sorbitol was found to be inversely correlated with the concentration of AA in the erythrocytes. A human supplementation study was conducted with 10 normoglycemic subjects. Each was given 500 mg/day AA alone or in a citrus fruit medium. Each supplementation lasted 2 wk and was followed by a 10-day wash-out. The citrus fruit medium produced a significantly greater increase in erythrocyte AA compared with AA alone. AA alone and in citrus fruit medium decreased erythrocyte sorbitol 12.6% and 27.2%, respectively, with the latter being significantly more effective. In a study with 4 subjects, 2000 mg/day AA resulted in a reduction in erythrocyte sorbitol of 56.1%. As in the in vitro study, there was an inverse relationship between erythrocyte AA and sorbitol. Two thousand milligrams of AA per day (AA or citrus fruit medium) was given to 8 diabetic subjects in a preliminary 3-wk supplementation trial in which erythrocyte sorbitol levels were decreased by 44.5%. These results suggest that AA supplementation for diabetic subjects may provide a simple means of preventing and ameliorating the complications of diabetes without the use of drugs.**

Sorbitol, produced by the reduction of glucose in a reaction catalyzed by the enzyme aldose reductase, has been implicated as a causative factor in the long-term complications of diabetes. These complications include cataracts, neuropathy, retinopathy, and nephropathy. They arise in tissues in which the transport of glucose is insulin

independent. Sorbitol accumulates in proportion to the extracellular concentration of glucose in sensitive tissues; notably the lens, retina, aorta, renal papilla, and peripheral nerve (1). Drugs that lower sorbitol concentrations by inhibiting aldose reductase allow new treatment possibilities for the complications of diabetes (2,3).

Ascorbic acid (AA) concentration and turnover in the plasma of diabetic individuals have been found to be lower than normal (4,5). Glucose has been found to inhibit the in vitro uptake of AA and its reduced form dehydroascorbic acid in granulocytes (6), endothelial cells (7), neutrophils and fibroblasts (8,9), and erythrocytes (10). Chen et. al. (11) have recently shown that in diabetic subjects intravenous glucose administration and the resultant hyperglycemia caused a marked depletion of leukocyte AA that did not recover within 1 h, which was in contrast with findings from normal subjects. The transport of AA has been shown to be enhanced by insulin (12,13). Thus, diabetic individuals who have low insulin and high glucose levels may be at a double disadvantage with respect to AA uptake and storage and would be expected to develop a "local scurvy" as hypothesized by Mann and Newton (14).

Our group has recently found that supplemental AA slowed down the progression of galactose-induced cataracts in rats, a diabetic cataract animal model (15). AA also was found to diminish the production of dulcitol, the galactose analogue of sorbitol, in lenses incubated in a high-galactose medium. In a single-dose human study, 500 mg of AA in a citrus fruit media was found to absorb better than AA alone (16). These findings led us to investigate the effect of AA and citrus fruit media on in vitro and in vivo sorbitol production in human erythrocytes.

## RESEARCH DESIGN AND METHODS

**Forms of AA.** AA crystals were obtained from Fisher (Pittsburgh, PA). AA tablets, 500 and 1000 mg, were distributed by Fay Drugs (Liverpool, NY). Citrus fruit medium, a tan powder (Foodform® Vitamin C) was used which contained 25.1% AA, 19.5% bioflavonoids, 25% carbohydrates, and 27% protein. Caplets of 250 mg AA or citrus fruit medium (Foodform® Vitamin C) were used. The ascorbate in the citrus fruit medium was measured in our laboratory by high-performance liquid chromatography (HPLC) after protein precipitation (17). The bioflavonoids in the citrus fruit medium were identified and quantified by HPLC and found to contain 81.8% naringenin and 18.2% hesperidin (18).

**Incubation.** Whole blood was collected in EDTA tubes from a single adult volunteer by fingerstick sampling with a lancet. The blood was immediately centrifuged to separate the erythrocytes from the plasma. The erythrocytes were washed three times with isotonic saline and centrifuged.

A modification of the incubation procedure of Malone (19) was used. One hundred microliters of erythrocytes were immediately added to 1 ml of Hanks' balanced salt solution (Sigma, St. Louis, MO), which had been previously adjusted to pH 7.4. One milliliter of Hanks' solution was used for the control sample, or 1 ml of AA freshly dissolved in Hanks' solution was used for the AA samples. These solutions were incubated at 37° C for 3 h in an atmosphere of 95% air/5% CO<sub>2</sub>. The cells were centrifuged, washed with saline,<sup>2</sup> and centrifuged again. The protein was precipitated with 2 ml of cold 6% perchloric acid. The solutions were stored at -20° C until analysis.

**Human supplementation.** Ten subjects (3 women, 7 men), aged 18-44 yr, volunteered for the study with informed consent. They were normoglycemic (4.03 ± 0.72mM) determined by hexokinase assay of fasting plasma (Sigma). Each subject was tested in the morning after an overnight fast. Blood was collected with a fingerstick lancet, and the separated erythrocytes were stored at -20° C after protein precipitation with 6% perchloric acid.

Each subject took 500 mg AA/day in the form of AA tablets or citrus fruit medium powder in a random crossover design. The citrus fruit medium was measured by volume. The subjects were instructed to take the supplement at breakfast. After 2 wk of supplementation and an overnight fast, blood samples were obtained from the subjects 24 h after the last supplementation when AA levels had returned to baseline (16). A 10-day washout was followed by another sampling. The second supplementation was then given for 2 wk and another sample taken. A paired Student's t test was used for statistical analysis.

A second supplementation study involved four normoglycemic men, aged 18-44 yr, from the previous study. Samples were obtained as before, and the subjects were given 2000 mg AA/day in the form of 1000-mg AA tablets. They were instructed

to take one tablet with the morning meal and one with the evening meal. After 2 wk, samples were obtained again.

Eight diabetic (5 insulin-dependent and 3 non-insulin-dependent) subjects participated in a 3-wk supplementation study after giving informed consent. There were six women and two men with an average ( $\pm$ SD) age of  $47 \pm 17$  yr (range 16-68 yr) and an average duration of diabetes of 15.2 yr. The average ( $\pm$ SD) fasting plasma glucose for the subjects was  $9.17 \pm 2.97$  mM. The subjects were divided into two groups for supplementation. Each group contained three women and one man with no significant difference in age or duration of diabetes. The subjects took four 250-mg caplets of AA in the form of AA or citrus fruit medium twice a day with meals for a total daily dose of 2000 mg of AA. Sampling was done before and 3 wk after supplementation.

**Analysis of AA.** A modification of the fluorometric method of Hubman et al. (20) was used for the analysis of AA in erythrocytes. This assay uses 1,2-naphthoquinone-4-sulfonic acid as the fluorometric reagent and measures only unoxidized AA in the erythrocytes. The supernatant from the protein precipitation of the erythrocyte was mixed with an equal volume of 1 M K CO before analysis.

The concentration of AA in the erythrocytes of the single person used for the in vitro study was  $29.6 \pm 4.1$   $\mu$ M, which is similar to the average found in unsupplemented normal individuals (43  $\mu$ M) reported by Evans et al. (21).

**Analysis of sorbitol.** The enzymatic assay of Clements et al. (22) was used to measure the concentration of sorbitol in erythrocytes. Sorbitol is converted to fructose with sorbitol dehydrogenase and the resultant reduction of NAD<sup>+</sup> to NADH is measured fluorometrically. A Perkin-Elmer model LS-3 digital fluorometer was used with an NAD<sup>+</sup> concentration of 0.2mM. The sensitivity of the method was found to be 0.5 nmol/ml. Adding AA did not affect the development of the fluorescence. The concentration of sorbitol in the erythrocytes used for the incubation study was 17.6 nmol/ml, which is within the reported normal range of 10-27 nmol/ml (23).

## RESULTS

The data from multiple incubations of the same erythrocytes with different concentrations of AA in the medium are shown in Table 1. Hanks' solution has a concentration of 5.56 mM glucose in the medium, which simulates normoglycemia.

**Medium AA and erythrocyte AA.** The concentration of the AA in the erythrocyte should increase with increasing concentration of AA in the medium and then reach a plateau because the transport process is a saturable one (9). However, the data in Table 1 show that the AA concentration in the erythrocyte is biphasic, reaching a maximum and declining. When the concentration of AA in the medium is 10-100 times higher than physiological concentration (284 and 2840  $\mu$ M), the erythrocyte AA is constant and not significantly different from that found in erythrocyte incubated without AA in the medium. This may be attributed to the hemolytic effect of high AA concentrations on erythrocytes, which results in the destruction of AA (24). As expected, a greatly increased hemoglobin concentration in the medium was observed after incubation when the initial AA concentration was much higher than the physiological concentration. Another mechanism for the lack of increase of erythrocyte AA at higher than physiological levels of AA in the medium is the increasing efflux of AA, as seen by Khatami et al. (25) and Socci and Delamere (26) at high AA concentrations in the medium of cultured cells.

Table 1


**Effect of different concentrations of ascorbic acid (AA) in medium on concentration of AA and sorbitol**

Medium AA ( $\mu$ M)	n	Erythrocyte AA ( $\mu$ M)	Erythrocyte sorbitol (nmol/ml)
0 (Control)	6	$14.7 \pm 0.4$	$46.4 \pm 1.6$
2.84	6	$15.7 \pm 0.4^*$	$10.3 \pm 2.0^*$
14.2	4	$16.8 \pm 0.3^*$	$6.7 \pm 1.9^*$
28.4	6	$17.7 \pm 0.9^*$	$0.8 \pm 0.5^*$
142	3	$16.0 \pm 0.4^*$	$11.2 \pm 0.3^*$
284	4	$14.7 \pm 0.4$	$31.5 \pm 1.7^*$
2840	3	$14.4 \pm 0.0$	$27.8 \pm 2.4^*$

Erythrocytes incubated at 37°C for 3 h in Hanks' solution containing 5.56 mM glucose. Values are means  $\pm$  SD. n = number of replicate experiments.

\*P < .001 by 2-tailed Student's t test compared with control.


**Sorbitol and AA.** The concentration of sorbitol in the erythrocytes after incubation without AA (46.4 nmol/ml) is much greater than the preincubation value of 17.6 nmol/ml, an effect also observed by Morrison et al. (27). All incubations with AA produced a significant decline in erythrocyte sorbitol relative to the control without added AA (Table 1;  $P < .001$ ). Figure 1 shows a biphasic effect of AA on the percentage inhibition of sorbitol relative to the control, which contained no AA in the medium. Almost complete inhibition of sorbitol (98.3%) occurs at a medium AA concentration of 28.4  $\mu\text{M}$ . A similar level and pattern of inhibition was seen when citrus fruit medium was incubated in the medium instead of AA (data not shown).



**FIG. 1.** Effect of medium ascorbic acid (AA) concentration on reduction of erythrocyte (red blood cell) sorbitol relative to control with no AA in medium.

The biphasic effect of AA on sorbitol disappears when the concentration of AA in the erythrocyte is plotted against the concentration of sorbitol in the erythrocyte. (Fig. 2). An inverse exponential relationship exists between erythrocyte AA and

erythrocyte sorbitol. At low values of erythrocyte AA, the concentration of sorbitol increases exponentially, indicating by analogy that in scurvy or individuals with low erythrocyte AA the sorbitol levels will be high. At higher concentrations of erythrocyte AA, the sorbitol levels approach 0 as a limit. Note that the maximum erythrocyte AA concentration corresponds to the greatest sorbitol reduction (Table 1). These in vitro data indicate that AA supplementation should lower erythrocyte sorbitol.



**FIG. 2.** In vitro relationship between erythrocyte (red blood cell) ascorbic acid and red blood cell sorbitol.

**Human supplementation studies with normal subjects.** The average baseline value for the 10 subjects' erythrocyte AA was 32.8  $\mu\text{M}$  with a range of 29.7-36.8. The average baseline concentration of erythrocyte sorbitol was 19.6 nmol/ml with a range of 17.4-22.1 and is similar to that reported by Akgun et al. (23). For all supplementations, after the washout, the AA and sorbitol concentrations were not significantly different from the baseline values.

Table 2

**Effect of 500 mg/day of ascorbic acid (AA) supplementation as AA alone or in citrus fruit medium for 2 wk on erythrocyte AA and sorbitol of 10 normoglycemic subjects**

Supplement	Erythrocyte AA ( $\mu\text{M}$ )			Erythrocyte sorbitol (nmol/ml)		
	Before	After	Change	Before	After	Change
AA	33.2 $\pm$ 2.8	44.8 $\pm$ 5.4*	+35.4 $\pm$ 19.4%	19.5 $\pm$ 1.5	17.0 $\pm$ 1.4*	-12.6 $\pm$ 4.9%
Citrus fruit medium	32.4 $\pm$ 3.8	48.8 $\pm$ 15.4†	+57.5 $\pm$ 34.8%‡	19.7 $\pm$ 1.4	14.3 $\pm$ 2.5*	-27.2 $\pm$ 10.5%§

Values are means  $\pm$  SD.

\* $P < .001$ , † $P < .01$ , vs. before supplementation.

‡ $P < .05$ , § $P < .01$ , citrus fruit medium vs AA.

The results of the first supplementation with 500 mg of AA as in the form of AA or citrus fruit medium are shown in Table 2. Individual percentage changes were calculated and the data averaged. Both forms of AA significantly increased erythrocyte AA ( $P < .001$  for AA,  $P < .01$  for citrus fruit medium). The average percent increase in erythrocyte AA was 35.5% for AA and 57.5% for citrus fruit medium. In comparing the two forms, citrus fruit medium produced a significantly greater percent increase in erythrocyte AA ( $P < .05$ ). The greater effectiveness of citrus fruit medium in elevating AA can be attributed to its greater bioavailability as shown in the previous human absorption study (16).

The most dramatic difference between the two forms of AA is seen in the sorbitol data (Table 2). The AA produced a small but highly significant 12.6% reduction of erythrocyte sorbitol (range 8.1-19.9%). Even though the effect was small, all of the 10 subjects experienced a reduction. Citrus fruit medium caused a highly significant 27.2% decline in erythrocyte sorbitol (range 15.1-43.0%) with all subjects experiencing a decline. The citrus fruit medium produced over a twofold greater reduction than the AA, and the difference between the two forms was significant ( $P < .01$ ). The greater ability of citrus fruit medium to lower erythrocyte sorbitol can be attributed to its greater effectiveness in increasing erythrocyte AA.

The four subjects who took 2000 mg AA/day had a change in erythrocyte AA from  $33.3 \pm 2.68$  to  $130 \pm 4.8 \mu\text{M}$ , an average increase of 291%. At the same time the erythrocyte sorbitol went from  $19.4 \pm 1.5$  to  $8.1 \pm 2.0 \text{ nmol/ml}$ , an average decrease of 56.1%. This dosage of AA produced a significantly greater increase in erythrocyte AA and reduction of erythrocyte sorbitol than did either of the two forms of AA at 500 mg/day ( $P < .001$ ). The erythrocyte AA and sorbitol data were pooled for all the supplementation studies with normal subjects (Fig.3) The points define an exponential curve that has a shape very similar to that seen in Fig. 2 for the in vitro study except that erythrocyte sorbitol appears to approach 8 nmol/ml as a limit rather than 0.




FIG. 3. In vivo relationship between erythrocyte (red blood cell) ascorbic acid and red blood cell sorbitol.

Table 3

Effect of 2000 mg/day of ascorbic acid (AA) supplementation as AA alone or in citrus fruit medium for 3 wk on plasma and erythrocyte sorbitol of 8 diabetic subjects

Supplement	n	Plasma AA ( $\mu\text{M}$ )		Erythrocyte sorbitol (nmol/ml)	
		Before	After	Before	After
AA	4	$31.7 \pm 15.0$	$54.4 \pm 10.0^*$	$50.0 \pm 17.7$	$26.1 \pm 17.2^*$
Citrus fruit medium	4	$35.0 \pm 8.3$	$55.6 \pm 5.0^\ddagger$	$52.3 \pm 24.8$	$30.7 \pm 14.3$
Combined groups	8	$33.3 \pm 11.1$	$54.9 \pm 7.2^\ddagger$	$51.2 \pm 20.0$	$28.4 \pm 14.9^\ddagger$

Values are means  $\pm$  SD. n = number of subjects in each group.

\* $P < .05$ ,  $^\ddagger P < .01$ ,  $^\ddagger P < .001$ , vs. before supplementation.


**Diabetic supplementation.** The results of the supplementation of eight diabetic subjects with 2000 mg AA/day in the form of AA or citrus fruit medium for a 3-wk period are shown in Table 3. The data from the AA and citrus fruit medium groups were combined because there was no significant difference between the groups. Both forms of AA produced a significant increase in plasma AA, averaging 64.9% for the combined groups ( $P < .001$ ). AA supplementation produced an average decrease in erythrocyte sorbitol of 44.5%, a change that was highly significant. As in the in vitro and in vivo normoglycemic studies, the diabetic study also showed an inverse relationship between AA and erythrocyte sorbitol.

## DISCUSSION

The results of both the in vitro incubation of erythrocytes with normal concentrations of glucose and in vivo supplementation studies with normoglycemic subjects indicate that increasing the erythrocyte AA produces a greatly diminished sorbitol concentration. Although only erythrocytes were studied, it has been found by Malone et al. (28) that erythrocyte sorbitol correlates with sorbitol in the lens and sciatic nerve, two sites for diabetic complications. Thus, AA may prove useful for the prevention and treatment of the complications of diabetes. It has already been shown to be effective in retarding the progression and accelerating the regression of galactose cataracts in rats, an animal model of diabetic cataracts (15).


As a result of the greater effectiveness of 2000 vs 500 mg AA/day given to normal subjects, a preliminary 3-wk supplementation study was conducted with eight diabetic subjects who were given 2000 mg AA/day or citrus fruit medium. A comparison of this dosage of AA on the plasma AA of normal and diabetic subjects is shown in Fig. 4. In contrast to other reports, the diabetic subjects in this study had identical concentrations of plasma AA to that of normal subjects (33.3  $\mu\text{M}$ ). This may simply be due to the small number of subjects in this study. The 65% increase in the plasma AA of diabetic subjects was significantly less ( $P < .001$ ) than the 291% increase seen in the normal subjects in this study and less than the 162% increase found in normal subjects by Evans et al. (21). This

difference may be attributed to the hyperglycemic conditions in the diabetic subjects. Hyperglycemia has been shown to inhibit the uptake of AA in tissues (6-10). For the diabetic subjects, there was no difference in the plasma AA when given in the form of AA or citrus fruit medium, which is in contrast to the normal subject supplementation with 500 mg AA/day. This could be caused by a saturation of the body AA pool with the large dosage of AA.



**FIG. 4.** Comparison of effect of 2000 mg/day ascorbic acid (ascorbate, AA) supplementation on plasma AA of normal and diabetic subjects. N Pre, AA normal subjects before supplementation; N Post, normal subjects after supplementation; D Pre, diabetic subjects before supplementation; D Post, diabetic subjects after supplementation.

Figure 5 shows a comparison of the erythrocyte sorbitol of normal and diabetic subjects. As expected, the diabetic subjects had significantly higher baseline sorbitol levels than normal subjects (51.2 vs 19.4 nmol/ml, respectively;  $P < .01$ ). After supplementation, the erythrocyte sorbitol of diabetic subjects was not significantly different ( $P > .05$ ) from the normal subjects before supplementation (28.4 and 19.4 nmol/ml, respectively). Thus, AA in the form of either AA or citrus fruit medium effectively normalized erythrocyte sorbitol of diabetic subjects. The 44.5% decrease in erythrocyte sorbitol produced by AA supplementation in the diabetic subjects is similar to the 52% reported by Malone et al. (28) after 2 wk of therapy with sorbinil at a dosage that caused side effects in one-third of the subjects in a long-term study (29). Our subjects reported no ill effects with AA.



**FIG. 5. Comparison of effect of 2000 mg/day ascorbic acid supplementation on erythrocyte (red blood cell) sorbitol of normal and diabetic subjects. N Pre, normal subjects before supplementation; N Post, normal subjects after supplementation; D Pre, diabetic subjects before supplementation; D Post, diabetic subjects after supplementation.**

The mechanism of the effect of AA on sorbitol is unknown. AA is a well-documented physiological antioxidant, and its role has been recently reviewed (30). Previous *in vitro* (31) and *in vivo* (32) studies have shown that AA is a very effective antioxidant in the lens. It has been proposed that AA functions by its physiological oxidation, which consumes NADPH indirectly through the glutathione redox couple (31). In our laboratory, AA has been found to rapidly consume NADPH in the presence of glutathione (J.A.V. and H.-W. Wang, unpublished observations). This results in less NADPH being available for sorbitol formation from glucose. Under hyperglycemic conditions, an alteration in pyridine nucleotide redox ratios produces an oxidative stress that may result in diabetic complications. Other antioxidants have been shown to reduce this oxidative stress *in vitro* (33).

If AA acts by a different mechanism than aldose reductase inhibitors it may prove to be synergistic with these drugs and be useful as an adjunct therapy for diabetic patients, thus allowing lower dosages of these drugs with subsequently fewer side effects. Note that in this study AA has been shown to be effective *in vitro* and *in vivo* in lowering sorbitol under normoglycemic conditions when sorbinil is ineffective (31). Tolrestat, an aldose reductase inhibitor, has recently been shown to elevate plasma AA in diabetic rats (35). The

beneficial effect of aldose reductase inhibitors may be due at least in part to their beneficial effect on tissue AA. Studies are in progress to determine the long-term effectiveness of AA and citrus fruit medium supplementation for diabetic individuals.

## ACKNOWLEDGMENTS

We thank Debbie Camp for secretarial assistance and Joseph Dreisbach for reviewing the manuscript and useful suggestions.

## REFERENCES

1. Kador PF, Kinoshita JH: Role of aldose reductase in the development of diabetes-associated complications. *Am J Med* 79:8-12, 1985
2. Kador PF, Robison WG Jr, Kinoshita JH: The pharmacology of aldose reductase inhibitors. *Annu Rev Pharmacol Toxicol* 25:691-714, 1985
3. Kador PF, Sharpless NE, Kinoshita JH: Aldose reductase inhibitors: a potent new class of agents for the pharmacological control of certain diabetic complications. *J Med Chem* 28:847-49, 1985
4. Chatterjee IB, Majumder AK, Nandi BK, Subramanian N: Synthesis and some major functions of vitamin C in animals. *Ann NY Acad Sci* 258:368-73, 1975
5. Stankova L, Riddle M, Larned J, Burry K, Menashe D, Hart J, Bigley R: Plasma ascorbate concentrations and blood cell dehydroascorbate transport in patients with diabetes mellitus. *Metabolism* 33:347-53, 1984
6. Moser U, Weber F: Uptake of ascorbic acid by human granulocytes. *Int J Vitam Nutr Res* 54:47-53, 1984
7. Kapeghian JC, Verlangieri AJ: The effects of glucose on ascorbic acid uptake in heart endothelial cell: possible pathogenesis of diabetic angiopathies. *Life Sci* 34:577-84, 1984
8. Bigley R, Wirth M, Layman D, Riddle M, Stankova L: Interaction between glucose and dehydroascorbate transport in human neutrophils and fibroblasts. *Diabetes* 32:545-48, 1983
9. Padh H, Subramoniam A, Aleo JJ: Glucose inhibits cellular ascorbic acid uptake by fibroblasts *in vitro*. *Biol Int* 9:531-38, 1985
10. Mann GV, Newton P: The membrane transport of ascorbic acid. *Ann NY Acad Sci* 258: 243-52, 1975
11. Chen MS, Hutchinson ML, Pecoraro RE, Lee WYL, Labbe RF: Hyperglycemia-induced intracellular depletion of ascorbic acid in human mononuclear leukocytes. *Diabetes* 32:1078-81, 1983
12. Verlangieri AJ, Sestito J: Effect of insulin on ascorbic acid uptake by heart endothelial cell: possible relationship to retinal atherogenesis. *Life Sci* 29:1-5, 1981
13. Berhanu P, Olefsky JM: Effects of insulin and insulin like agents on the glucose transport system of cultured human fibroblasts. *Diabetes* 30:523-29, 1981

14. Mann GV, Newton P: Hypothesis: the role of vitamin C in diabetic angiopathy. *Perspect Biol Med* 17:210-17, 1974
15. Vinson JA, Possanza CJ, Drack AV: The effect of ascorbic acid on galactose-induced cataracts. *Nutr Rep Int* 33:665-69, 1986
16. Vinson JA, Bose P: Bioavailability of sythetic ascorbic acid and a citrus extract (Abstract). *NY Acad Sci* 498: 525-26, 1987
17. Ziegler SJ, Meier B: Fast and selective assay of ascorbic acid in rose hips by RP-HPLC coupled with electrochemical and/or spectrophotometric detection. *Planta Med* 5:383-87, 1983
18. Park GL, Avery SM, Byers JL, Nelson DB: Identification of bioflavonoids from citrus. *Food Technol* 37:98 105, 1983
19. Malone JI, Knox G, Benford S, Tedesco TA: Red cell sorbitol: an indicator of diabetic control. *Diabetes* 29:861 64, 1980
20. Hubman B, Monnier D, Roth M: Une methode de dosage rapide et precise de l'acide ascorbique: application a la mesure des taux plasmatiques. *Clin Chim Acta* 25:161 66, 1969
21. Evans RM, Currie L, Campbell A: The distribution of ascorbic acid between various cellular components of blood, in normal individuals, and its relation to the plasma concentration. *Br J Nutr* 47:473-82, 1982
22. Clements RS Jr, Morrison AD, Winegrad AI: Polyol pathway in aorta: regulation by hormones. *Science* 166: 1007-1008, 1969
23. Akgun S, Ertel NH, Kemp FW: Red blood cell sorbitol and diabetic control. *Horm Metab Res* 45:355-57, 1985
24. Mengel GE, Greene HL Jr: Ascorbic acid effects on erythrocytes (Letter). *Ann Intern Med* 84:490, 1976
25. Khatami M, Stramm LE, Rockey JH: Ascorbate transfer in cultured cat retinal pigment epithelial cells. *Exp Eye Res* 43:607-12, 1986
26. Socci RR, Delamere NA: Characteristics of ascorbate transport in the rabbit iris-ciliary body. *Exp Eye Res* 46:853-61, 1988
27. Morrison AD, Clements RS, Travis SB, Oski F, Winegrad AI: Glucose utilization by the polyol pathway in human erythrocytes. *Biochem Biophys Res Commun* 40:199 205, 1970
28. Malone JI, Leavengood H, Peterson MJ, O'Brien MM, Page MG, Aldinger CE: Red blood cell sorbitol as an indicator of polyol pathway activity: inhibition by sorbinil in insulin-dependent diabetic subjects. *Diabetes* 33:45 49, 1984
29. Martyn CN, Matthews DM, Popp-Snijders C, Tucker J, Ewing DJ, Clarke BF: Effects of sorbinil treatment on erythrocytes and platelets of persons with diabetes. *Diabetes Care* 9:36-39, 1986
30. Bendlich A, Machlin LJ, Scandiana O, Burton GW, Wagner DDM: The antioxidant role of vitamin C. *Free Radical Biol Med* 2:419-44, 1986
31. Varma SD, Kumar S, Richards RD: Light-induced damage to ocular lens cation pump: prevention by vitamin C. *Proc Natl Acad Sci USA* 76:3504-506, 1979
32. Organisciak DT, Wang H-M, Li Z-Y, Mark OMT: The protective effect of ascorbate in retinal light damage of rats. *Invest Ophthalmol Visual Sci* 26:1580-87, 1985
33. Williams WF, Odom JD: The utilization of 13 C and 31P nuclear magnetic resonance spectroscopy in the study of the sorbitol pathway and aldose reductase inhibition in intact rabbit lenses. *Exp Eye Res* 47:717-30, 1987
34. Gonzalez A-M, Sochor M, McLean P: Effect of an aldose reductase inhibitor (sorbinil) on the level of metabolites in the lenses of diabetic rats. *Diabetes* 32:482-85, 1983
35. Yue DK, McLennan S, Fisher E, Heffernan S, Capogreco C, Ross GR, Turtle JR: Ascorbic acid metabolism and polyol pathway in diabetes. *Diabetes* 38:257-61, 1989

This information is intended solely for informational and educational purposes, not for medical advice. IntraCell Nutrition Inc. strongly recommends that consumers consult a physician for health problems or questions they may have. These studies may not conform to peer review standards. Therefore, the results are not conclusive.